KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS
The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma.La présente invention concerne une molécule de ligand qui se lie spécifiquement à KTR3DL2 à la surface de lymphocytes T malins exprimant KTR3DL2 dans le traitement des lymphomes. Linvention concerne également lutilisation in vitro dun niveau dexpression de KTR3DL2 qui est un biomarqueur utile pour le diagnostic et/ou la surveillance dun lymphome.
